Format

Send to

Choose Destination
Pharmacol Ther. 2015 Nov;155:1-10. doi: 10.1016/j.pharmthera.2015.07.007. Epub 2015 Jul 26.

CD70: An emerging target in cancer immunotherapy.

Author information

1
Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium. Electronic address: julie.jacobs@uantwerpen.be.
2
Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
3
Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
4
Department of Oncology, Antwerp University Hospital, Edegem, Belgium; Phase 1-Early Clinical Trials Unit, Antwerp University Hospital, Edegem, Belgium.
5
arGEN-X BVBA, Ghent, Belgium.
6
Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium.
7
Center for Oncological Research, University of Antwerp, Wilrijk, Belgium.
8
Center for Oncological Research, University of Antwerp, Wilrijk, Belgium; Laboratory of Experimental Hematology (LEH), Vaccine and Infectious Disease Institute, University of Antwerp, Edegem, Belgium.

Abstract

Over the last decades, advances in the knowledge of immunology have led to the identification of immune checkpoints, reinvigorating cancer immunotherapy. Although normally restricted to activated T and B cells, constitutive expression of CD70 in tumor cells has been described. Moreover, CD70 is implicated in tumor cell and regulatory T cell survival through interaction with its ligand, CD27. In this review, we summarize the targetable expression patterns of CD70 in a wide range of malignancies and the promising mechanism of anti-CD70 therapy in stimulating the anti-tumor immune response. In addition, we will discuss clinical data and future combination strategies.

KEYWORDS:

CD27; CD70; Cancer immunotherapy; Combination therapy

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center